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Abstract Therapeutic attempts to cure Alzheimer’s disease
(AD) have failed, and new strategies are desperately needed.
Motivated by this reality, many laboratories (including our
own) have focused on synaptic dysfunction in AD because
synaptic changes are highly correlated with the severity of
clinical dementia. In particular, memory formation is accom-
panied by altered synaptic strength, and this phenomenon (and
its dysfunction in AD) has been a recent focus for many
laboratories. The molecule cyclic adenosine monophosphate
response element-binding protein (CREB) is at a central con-
verging point of pathways and mechanisms activated during
the processes of synaptic strengthening and memory forma-
tion, as CREB phosphorylation leads to transcription of
memory-associated genes. Disruption of these mechanisms
in AD results in a reduction of CREB activation with accom-
panying memory impairment. Thus, it is likely that strategies
aimed at these mechanisms will lead to future therapies for
AD. In this review, we will summarize literature that investi-
gates 5 possible therapeutic pathways for rescuing synaptic
dysfunction in AD: 4 enzymatic pathways that lead to CREB
phosphorylation (the cyclic adenosine monophosphate cas-
cade, the serine/threonine kinases extracellular regulated ki-
nases 1 and 2, the nitric oxide cascade, and the calpains), as
well as histone acetyltransferases and histone deacetylases (2
enzymes that regulate the histone acetylation necessary for
gene transcription).
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Introduction
For years the debate over the causes of Alzheimer’s disease
(AD) was dominated by 2 major neuropathologic hallmarks:
amyloid plaques, consistingmostly of extracellular deposits of
amyloid-beta (Aβ) peptides, a downstream product of the
processing of the larger amyloid precursor protein (APP);
and neurofibrillary tangles (NFTs), consisting mostly of
intraneuronal accumulations of hyperphosphorylated tau pro-
tein. However, neither the degree of amyloid plaque nor NFT
pathology are as highly correlated with the severity of clinical
dementia as synaptic pathology [1]. Both pathogenic Aβ and
tau assemblies could, in turn, alter the mechanisms underlying
the excitatory response at single synapses producing synaptic
dysfunction before synapse loss [2]. Faltering of the synapses
at early stages of the disease would underlie subtle amnesic
problems in patients with AD. These events would open up a
temporal frame during which it might be still possible to
intervene therapeutically before any irreversible damage has
occurred. Because of this possibility our laboratories and
many others have focused their research on the identification
of the molecular mechanisms responsible for synaptic dys-
function, in particular mechanisms that impair long-term po-
tentiation (LTP), a type of synaptic strengthening that is likely
to underlie learning and memory. A particularly interesting
study that developed this idea came from the laboratories of
Lloyd Green and Michael Shelanski at Columbia University,
where Aβ exposure was found to regulate a group of genes
that interfere with the memory and synaptic plasticity mole-
cule cyclic adenosine monophosphate (cAMP) response
element-binding protein (CREB) in nerve growth factor-
primed PC12 cells [3]. CREB is phosphorylated during
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memory processes by activation of a series of second messen-
ger systems [4–7]. Its phosphorylation leads to binding to
CREB binding protein (CBP), a histone acetyltransferase
(HAT) that (similar to other HATs) functions as a co-
activator that catalyzes histone acetylation, causing an in-
crease in the transcription of memory-associated genes
[8–13]. This effect on acetylation is counteracted by histone
deacetylases (HDACs) which were found to remove an acetyl
group from histones, thus reducing gene expression levels. It
is therefore likely that derangement of the enzymatic path-
ways leading to CREB phosphorylation, as well as the tran-
scription machinery interacting with CREB during memory
formation, play a key role in synaptic dysfunction and mem-
ory loss in AD. Most importantly, targeting the enzymatic
pathways and the transcription machinery leading to memory
formation may be a useful strategy for treating AD. Here we
will summarize the literature supporting the idea of targeting 4
enzymatic pathways leading to CREB phosphorylation, in-
cluding the cAMP/protein kinase A (PKA)/CREB cascade,
the serine/threonine kinases extracellular regulated kinase
(ERK) 1 and ERK 2 (ERK1/2), the nitric oxide (NO) cascade,
and the calcium-activated neutral cysteine proteases
(calpains), as well as HATs and HDACs for a therapy against
AD.
cAMP/PKA/CREB Cascade
PKA is one of the canonical kinases involved in synaptic
plasticity. Discovered over 40 years ago [14], PKA consists
of 2 catalytic components and 2 regulatory components. Var-
ious extracellular signals (e.g., synaptic stimulation) induce
adenylyl cyclase to produce cAMP, which then binds to the
regulatory elements of PKA (PKA-R) resulting in dissociation
of PKA-R from the PKA catalytic components. This liberates
the PKA catalytic components, which can then phosphorylate
(and thus activate) CREB (see [4] for a recent review) (Fig. 1).
There is extensive literature examining PKA dysfunction in
animal models of AD, which may be induced through Aβ-
mediated oxidative stress [15], as well as through Aβ-
independent mechanisms, such as direct inhibition of the
PKA pathway by β-secretase (BACE)1 [16]. Moreover, the
antiamnestic effects of both caffeine and environmental enrich-
ment in animal models of AD have been linked to promotion of
PKA activity [17, 18]. As an aside, our group has shown that at
low physiologic (picomolar) levels, Aβ42 promotes memory
formation [19] (with its depletion reducing learning and mem-
ory [20]), and this effect has also been linked to enhancement of
the PKA pathway [21]. Finally, our group has shown that
pathologic (nanomolar) concentrations of Aβ42 cause a rapid
and sustained decrease in PKA activity and inhibition of CREB
phosphorylation in hippocampal neuronal cultures in response
to glutamate stimulation [3].
Given the importance of cAMP [as well as cyclic guano-
sine monophosphate (cGMP)—see below] in the central ner-
vous system, many neuroscientists have become interested in
the regulation of cAMP and cGMP. Both cyclic nucleotides
are primarily regulated by a family of enzymes called phos-
phodiesterases (PDEs). PDEs hydrolyze cAMP and cGMP
into 5’AMP and 5’GMP, respectively [22]. In particular,
PDE4 has been shown to be a major regulator of cAMP [23,
24]. Thus, PDE4 inhibition has been proposed as a therapeutic
strategy that can lead to cAMP elevation and increased CREB
phosphorylation. Rolipram is a prominent PDE4 inhibitor that
has been tested in multiple animal models of AD for this
reason [25]. For example, the APP/PS1 mouse model of AD
displays impaired synaptic plasticity and memory as early as
3–4 months of age [26], and our group has found that rolipram
rescues LTP, contextual fear conditioning, and spatial working
memory in these mice [27]. In this same study, it was shown
that improvements in synaptic plasticity and memory
persisted for several months after the last dose of rolipram,
and this was accompanied by a reversal of the observed
decrease in CREB phosphorylation in these mice. A separate
study by Cheng et al. [28] found that rolipram treatment
reversed the memory deficits seen in rats treated with Aβ1-
40. In this study, rolipram also reversed the memory deficits
caused by Aβ25-35 (the core fragment of Aβ1-40). Rescue of
memory impairment in this animal model was also accompa-
nied by an elevation of phosphorylated CREB. Finally, a third
study has examined the effects of PDE4 micro-RNA knock-
down in an additional rodent model of AD [29]. In this study,
PDE4 knockdown in mice reversed memory deficits caused
by hippocampal injection of Aβ1-42. Consistent with the
Fig. 1 A schematic representation of the cyclic adenosine
monophosphate (cAMP) signaling cascade. Activation of adenylyl cy-
clase (AC) leads to the formation of cAMP from adenosine triphosphate
(ATP). Phosphodiesterase 4 (PDE4) degrades cAMP in AMP. cAMP
activates protein kinase A (PKA), which phosphorylates cAMP-
responsive element-binding protein (CREB). CREB phosphorylation
activates the transcription machinery. DNA (red line) is part of the
transcription machinery. Of note, Uch-L1 activates proteasomal (Pr)
degradation of the PKA regulatory subunit, which also promotes CREB
phosphorylation through PKA activation. CRE = cAMP response ele-
ment; CBP = CREB binding protein; p = phospho group
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previous 2 studies, this improvement in memory was accom-
panied by an increase in phosphorylated CREB. The consis-
tency of the results across all of these studies supports the use
PDE4 inhibition as a treatment of memory dysfunction in AD.
As an aside, some have questioned the use of rolipram as an
antiamnestic in humans owing to its side effect of severe
emesis [30]. In response, newer PDE4 inhibitors have been
developed that improve memory without the side effects of
rolipram [31], and which are still effective months after chron-
ic treatment [32], similarly to rolipram.
All these data lead to the obvious question: Is there im-
paired PKA activity in the brains of patients with AD? Al-
though this question has not been answered directly, there is
circumstantial evidence to support this idea. The brains of
patients with AD show an accumulation of ubiquitinated
proteins [33], suggesting inhibition of the protein degradation
machinery. Could there be impaired degradation of PKA-R in
AD? If this were to occur, it would result in increased binding
of PKA-R to the PKA catalytic domain, which would lead to
increased inhibition of PKA. Uch-L1, a neuron- and testis-
specific enzyme, is associated with protein ubiquitination and
long-term facilitation in Aplysia [34, 35] (Fig. 1). In addition,
Uch-L1 is downregulated in AD brains [36]. There may also
be a loss of soluble Uch-L1 in AD brains; NFTs stain for Uch-
L1, and levels of soluble Uch-L1 are inversely proportional to
tangle burden [36]. This circumstantial evidence has generat-
ed interest in studying the mechanism of how decreased Uch-
L1 levels may contribute to synaptic dysfunction in AD. The
hypothesis is that Uch-L1 normally participates in the degra-
dation of the PKA-R protein, which then allows the PKA
catalytic domain to phosphorylate (i.e., activate) CREB.
Therefore, when Uch-L1 activity is impaired, PKA-R is not
degraded as quickly, the PKA catalytic domain is sequestered,
and CREB phosphorylation is impaired.
Our group has investigated the above hypothesis [37], and
we have shown that 1) Uch-L1 protein levels are reduced in
the hippocampus of APP/PS1 mice; 2) inhibiting Uch-L1
activity leads to an impairment of hippocampal LTP; and 3)
supplementing Uch-L1 protein restores LTP and associative
memory in APP/PS1 mice and blocks the Aβ-induced reduc-
tion in PKA activity [37]. Additional work has also shown that
Uch-L1 treatment can restore spine density in mouse models
of AD, and this effect is seen even in elderly mice [38]. Thus,
upregulating Uch-L1 activity may be a therapeutic strategy for
rescuing synaptic function in AD [39]. As an aside, Uch-L1
has also been shown to be associatedwith Parkinson’s disease.
Liu et al. [40] have shown that farnesylation promotes the
association of Uch-L1 with cellular membranes, and that this
correlates with α-synuclein pathology. The mechanism for
this association is unclear, but may relate to loss of
functional (soluble) Uch-L1 from the cytoplasm. In any
case, farnesyltransferase inhibition reduces α-synuclein
levels and improves cell survival in cultures, suggesting
that Uch-L1 may also be a therapeutic target for
Parkinson’s disease.
The ERK1/2 Mitogen-Activated Protein Kinase Pathway
Signaling cascades involving ERK1/2 constitute another path-
way that leads to CREB phosphorylation [41]. ERK1/2 are
components of 1 of 4 related, but distinct, mitogen-activated
protein kinase (MAPK) pathways that also include the c-Jun
N-terminal kinase/stress-activated protein kinase [42, 43], the
p38MAPK [44], and ERK5/bigMAP kinase 1 [45] pathways.
The canonical ERK signaling pathway consists of a molecular
cascade wherein receptor tyrosine kinase activation leads to
activation of the guanosine-5’-triphosphatase-activating pro-
tein, son of sevenless (SOS), via the adaptor proteins Shc and
Grb2 (Fig. 2). SOS then activates the small guanosine
triphosphate-binding protein, Ras, that initiates a 3-member
kinase cascade that is the hallmark of MAPK pathways. In the
case of ERK, this cascade consists of Raf, mitogen/
extracellular signal-regulated kinase and ERK1/2 [46]. CREB
phosphorylation occurs when ERK translocates to the nucleus
to phosphorylate CREB kinases. In the case of neurotrophin-
induced CREB phosphorylation, Msk1 appears to be the
critical kinase mediating CREB phosphorylation [47].
Fig. 2 A schematic representation of the canonical mitogen-activated
protein kinase (MAPK) signaling cascade. Receptor tyrosine kinase
activation leads to activation of the guanosine triphosphatase-activating
protein, son of sevenless (Sos), via the adaptor proteins Shc and Grb2,
and the small guanosine triphosphate-binding protein, Ras. Ras initiates a
3-member kinase cascade that, in the case of extracellular regulated
kinase (ERK), consists of Raf, mitogen/extracellular signal-regulated
kinase (MEK) and ERK1/2. CREB phosphorylation occurs when ERK
translocates to the nucleus to phosphorylate cyclic adenosine
monophosphate (cAMP)-responsive element-binding protein (CREB)
kinases. DNA indicated by red line. CRE = cAMP response element;
CBP = CREB binding protein; p = phospho group
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Support for the notion that ERK-induced CREB phosphor-
ylation may be beneficial for AD-related impairments comes,
in part, from studies of brain-derived neurotrophic factor
(BDNF) signaling. BDNF induces CREB phosphorylation
by binding to its cell surface receptor, TrkB, and activating
the ERK signaling cascade. BDNF has been found to enhance
synaptic plasticity and promote cell survival in model systems
[48, 49], both of which are potentially beneficial for AD.
Conversely, reduced levels of BDNF in patients with AD or
mild cognitive impairment may contribute to cognitive im-
pairments and disease progression in these individuals
[50–53]. Application of sublethal concentrations of Aβ
to neurons in culture has also been reported to interfere
with BDNF-induced activation of ERK and CREB phos-
phorylation [54].
Despite data suggesting a beneficial role for BDNF-
induced ERK signaling, evidence suggests that ERK signaling
plays a more complex role in AD. ERK can be activated by
multiple mechanisms and, in turn, can act on multiple targets.
In some cases data suggest that the effect of ERK signaling on
AD is likely to be beneficial, and in others that it is likely to be
detrimental. Elevated levels of ERK have been reported in the
cerebrospinal fluid of patients with AD [55], and increased
levels of activated ERK have been found in postmortem AD
brains [55–57]. A similar increase in activated ERK has also
been found in the brains of mice that overexpress a mutant
form of APP [58]. However, given that ERK is required for
normal learning and memory and normal synaptic plasticity
[59, 60], the extent to which these increases represent contrib-
utory or compensatory mechanisms for AD-related impair-
ments remains unclear.
Aβ-induced receptor activation is thought to be one of the
mechanisms leading to increased ERK activation in AD
brains. The ERK pathway is activated by a number of recep-
tors that bind Aβ, including the ionotropic and metabotropic
glutamate receptors N-methyl-D-aspartate and mGluR5
[61–65], the receptor for advanced glycation end products
[66, 67], the p75 neurotrophin receptor, integrins, and a num-
ber of microglial receptors (reviewed in [68]). Aβ also inter-
acts with alpha7 nicotinic receptors, which are required for
Aβ-induced ERK and CREB phosphorylation [58]. Finally,
APP itself may activate the ERK pathway via interactions
between its cytoplasmic domain and the adaptor proteins
Grb2 and ShcA [69]. To the extent that ERK signaling medi-
ates any of the toxic actions of Aβ, this pathway may also
contribute to AD. Data consistent with hypothesis come from
studies using a synthetic p75 neurotrophin receptor ligand,
LM11A-31, which was found to inhibit Aβ-induced synaptic
dysfunction and memory loss [70].
Excitotoxicity and dysregulated calcium homeostasis are
thought to occur in neurons affected by AD, and the resulting
increases in intracellular calcium can also activate the ERK
pathway via a number of molecular mechanisms [71, 72]. In
addition oxidative stress is thought to play a significant role in
AD pathogenesis and can similarly lead to ERK activation via
multiple pathways. Given that ERK activation of CREB in-
duces the expression of a number of antioxidant genes, acti-
vation of this pathway may represent an adaptive mechanism
to reduce oxidative damage (reviewed in [73]). This conten-
tion is supported by the observation that molecularly interfer-
ing with CREB increases seizure-induced cell death and pro-
duction of reactive oxygen species, and blocked the neuropro-
tective effect of BDNF [74].
In addition to CREB, the ERK pathway regulates 2 pro-
teins that are critically involved in AD: the microtubule-
associated protein, tau [75–81], and APP. In the case of tau,
hyperphosphorylation is thought to play a key role in AD
pathogenesis [82], and pharmacological inhibition of ERK1
ormolecular inhibition of its upstream activator, Ras, has been
found to prevent Aβ-induced increases in tau phosphorylation
[83, 84]. In contrast, ERK pathway regulation of APP pro-
cessing may protect against AD. ERK activation increases
soluble APPα production, a downstream product of APP
processing, and reduces production of the toxic Aβ peptide
[85, 86]. ERK inhibition also blocks the increase in Aβ
production caused by exposure to high concentrations of N-
methyl-D-aspartate in mice. These actions are owing, at least
in part, to ERK-dependent regulation of the activity and
expression of α- and γ-secretases, the 2 enzymes responsible
for APP processing [87–91].
Clearly, the ERK pathway and ERK-mediated CREB
phosphorylation play a critical role in AD. While significant
progress has been made in unraveling its complex molecular
interactions, we still lack a complete understanding of all the
ways in which this pathway affects the development and
progression of the disease. This understanding will be critical
for the future development of AD therapeutic strategies that
target this pathway
The NO Cascade
NO is a gaseous molecule released from the conversion of the
amino acid L-arginine to L-citrulline by the enzyme NO
synthase (NOS). In particular, the neural NO synthase, acti-
vated in response to Ca2+/calmodulin, is widely expressed in
the brain, especially in the cortex and hippocampus [92],
where it has been implicated in pre- and postsynaptic mech-
anisms underlying synaptic plasticity (for a review see [93]).
NO acts on soluble receptor guanylate cyclase (sGC) stimu-
lating the production of the second messenger cGMP, which,
in turn, is able to activate protein kinase G (PKG), the activity
of which maintains CREB phosphorylation at Ser133 [94, 95]
(Fig. 3). NO alsomediates CREB–DNA binding via a Ser133-
independent mechanism by the S-nitrosylation of nuclear
proteins associated with CREB target genes [96]. Various
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studies have suggested that NO/cGMP/PKG and cAMP/PKA
cooperate to ensure different phases of LTP and to underpin
memory acquisition and consolidation via CREB phosphory-
lation [94, 97–100]. CREB phosphorylation is now recog-
nized as a crucial event that regulates transcription during
synaptic plasticity [101–103], leading to protein synthesis
and the generation of new dendritic spines to ensure long-
term morphological changes associated with late LTP [104].
The NO/cGMP/PKG/CREB system is disrupted during
Aβ-induced suppression of synaptic plasticity. This occurs
through Aβ-mediated inhibition of NO-induced CREB phos-
phorylation [105–111], and toxicity may be exacerbated be-
cause the NO/cGMP signaling pathway exerts a protective
role against Aβ-mediated neurotoxicity [112–114]. We have
previously demonstrated that the use of NO donors or cGMP
agonists was able to rescue the Aβ-induced impairment of
LTP and CREB phosphorylation, whereas sGC or PKG inhi-
bition suppresses this neuroprotective effect [110]. Moreover,
sGC activity and cGMP production are blocked by Aβ in
brain astroglial cells and tetanized hippocampal slices [109,
110], as well as in temporal cortex of patients with AD [115].
As PKG phosphorylates (and activates) CREB [94], and
the therapeutic effect of cGMP analogs in the setting of
elevated Aβ requires PKG function [110], the beneficial ef-
fects of cGMP analogs on synaptic plasticity and memory in
the setting of elevated Aβmight involve CREB. Several lines
of evidence are consistent with this hypothesis: 1) the inhibi-
tion of 1 of the components of the NO/cGMP/PKG pathway
suppresses CREB phosphorylation [94, 116, 117]; 2) the
increase of phospho-CREB during synaptic plasticity is
blocked by Aβ in cultured cortical neurons [118], in cultured
hippocampal neurons [3], and in hippocampal tetanized slices
treated with Aβ [110]; and 3) stimulation of the NO/sGC/
cGMP pathway restores levels of phospho-CREB [112, 113].
Because of these findings, and considering that the NO cas-
cade is downregulated during aging and in neurodegenerative
disorders [112, 113, 119–122], an increasing number of
studies have focused on therapeutic strategies aimed to regu-
late this signaling pathway.
Other than classical nitrates or hybrid nitrates, NO donor
nonsteroidal anti-inflammatory drugs [123–127], an addition-
al therapeutic approach is to block the degradation of cGMP
by using PDE5 inhibitors (PDE5-Is). Over the past few years,
our group and others have demonstrated that treatment with
PDE5-Is rescues synaptic and memory deficits in the APP/
PS1mouse model of AD, restoring phospho-CREB levels and
decreasing Aβ load [112, 128]. The PDE5-I sildenafil also
exerts the same beneficial effect in a physiological mouse
model of aging [113], where it also inhibits apoptosis and
increases antiapoptotic molecules Bcl2 and BDNF [129].
The use of PDE5-Is to rescue cognitive function in AD is
intriguing, especially given our understanding of the relatively
benign side effect profile from long-term use of PDE5-Is to
treat male erectile dysfunction. Indeed, similarly to PDE4
inhibition [3], our data suggest that a temporary PDE5-I-
induced upregulation of CREB phosphorylation produces a
prolonged beneficial effect that extends beyond the duration
of the drug administration. Thus, acting on the NO/cGMP/
PKG/CREB pathway may not only counteract the effects of
high levels of Aβ, but it could also delay the progression of
the disease and prevent or reduce cognitive impairment.
Calpains
Calpains are a family of at least 15 proteases diffused through-
out the body with different specificities [130, 131]. Protein
cleavage is an activity typically directed at the catabolism of
peptides and protein. However, limited nondigestive proteol-
ysis is also a particular form of post-translational modification
changing both the activity and possibly the localization of cell
proteins [132]. Calpains are localized in the central nervous
systemwith 2 isoforms (calpain I and II) that are under intense
functional characterization [133]. Typically, calcium
Fig. 3 A schematic representation of the nitric oxide (NO) signaling
cascade. NO is formed from the conversion of aminoacid arginine to
citrulline by the enzyme neural NO synthase (nNOS). NO activates
soluble guanylate cyclase (sGC), which stimulates cyclic guanosine
monophosphate (cGMP) production from guanosine triphosphate
(GTP). cGMP is degraded in GMP by the enzyme phosphodiesterase 5
(PDE5). The increase of cGMP levels activates protein kinase G (PKG),
which induces cyclic adenosine monophosphate (cAMP)-responsive
element-binding protein (CREB) phosphorylation. DNA indicated by
red line. NADP = nicotinamide adenine dinucleotide phosphate; NADPH
= reduced form of nicotinamide adenine dinucleotide phosphate (NADP);
CRE = cAMP response element; CBP = CREB binding protein; p =
phospho group
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concentration-dependent driven autoproteolysis activates
calpains [134], and this phenomenon is dramatically increased
in neurodegenerative disease [135, 136]. Characteristically,
calpains clip a small portion of a protein (proactivation cleav-
age) determining the functional activation of the cleaved
protein. A straightforward example of this activity occurs with
CaMKIIα, protein kinase C, and PP3α/calcineurin, all pro-
teins involved in synaptic plasticity and memory mechanisms
[137–140], which are activated by calpains by cleavage of
their respective inhibitory domain [141–143] (Fig. 4).
Calpains hit many targets, including proteins and enzymes
involved in mechanisms of synaptic plasticity, learning and
memory, transcription factors such as CREB, and translational
factors like cytoplasmic polyadenylation element-binding
protein 3, a sequence-specific RNA-binding protein that re-
presses translation of its target mRNAs in neurons. Through
the regulation of CREB and cytoplasmic polyadenylation
element-binding protein 3 [144, 145], calpains indirectlymod-
ulate gene transcription or transduction. CREB is composed
of a C-terminal promoter-binding domain and an N-terminal
transcription regulation domain in which PKA can phosphor-
ylate the amino acid serine in position 133, a step required for
the regulation of gene expression along with the dimerization
and the inclusion in a transcription complex that includes CBP
[146]. Calpain-cleaved CREB preserves serine 133 phosphor-
ylation and recognizes cAMP response element sequences on
DNA while losing its major influence in activating the tran-
scription process [144, 145]. However, when calpains are
overactivated in response to overshoots of calcium influx,
such as in neurodegenerative disease like AD or ischemic
insults [136, 147–153], phosphorylated CREB levels decrease
and the phenomenon is accompanied by a decline of both
synaptic plasticity and memory [154].
The mechanisms behind the modulatory activity of
calpains on plasticity and memory are not well characterized
yet and several hypotheses have been proposed over time to
rationalize the proteolysis of key targets such as synaptic
receptors or kinase activity (see [133] for a recent review).
Di Rosa et al. [155] have shown that the cystein protease
inhibitor leupeptine decreases the frequency of spontaneous
release of neurotransmitter, suggesting a role of calpains in
neurotransmitter release. Moreover, calpastatin, the endoge-
nous inhibitor of the calpain system, unravels a function of
calpains in learning andmemory as rats deficient in calpastatin
show enhanced learning and memory [156]. An additional
activity is the tight regulation of PKA and, again, CREB
activity. Indeed, the decline of PKA levels by calpain activa-
tion or overactivation generates, in turn, a correspondent
increase in CREB truncation, and decrease in CREB phos-
phorylation and activation [145, 157], leading to decreased
plasticity and poor cognitive performance.
The mechanisms underlying synaptic plasticity are severely
impaired in AD from the early stages of the disease [1, 158,
159]. One of the culprits of AD is the overactivation of calpains
because of calcium homeostasis changes (see [160] for a critical
review). Enhanced calpain activation produces augmented APP
processing via BACE activation and augmented Aβ deposit
[161], increases tau-mediated neuropathology [162], and dis-
rupts the functionality of kinases such as CDK5 by pushing the
cleavage of the CDK5 activator p35 [163], but also induces
microgliosis, somatodendritic dystrophy, and increased mortal-
ity while the endogenous calpain inhibitor calpastatin is
knocked down in animal models of AD [164]. This evidence
supports the possible use of calpain inhibitors as a therapeutic
treatment in AD [153–155]. The field of medicinal chemistry is
currently engaged in producing a variety of molecules as pos-
sible calpain inhibitor candidates [165, 166]. Most of them are
chemically-related to a natural compound called E-64 that
irreversibly but not selectively inhibits calpains [167–169]. E-
64 exhibits excellent activity in transgenic models of AD
in vitro and in vivo [154, 170], rescuing the AD phenotype in
terms of synaptic plasticity and memory. However, the nonse-
lective nature of E-64 seems unfavorable for clinical use, so an
interesting development for this class of compounds against
AD is the development of a novel calpain I-selective
peptidomimetic, based on E-64 as a lead compound. Schiefer
et al. [171] designed a new series of derivatives with favorable
pharmacodynamic characteristics that maintain drug potency
while increasing calpain I selectivity and druggability [171].
BDA-410, an orally active synthetic Leu-Leu peptidomimetic
rescues synaptic plasticity defects and memory impairment in
an APP/PS1 AD mouse model but does not alter Aβ produc-
tions and increases CREB phosphorylation [154]. This fact
Fig. 4 A schematic representation of calpain activation with enzymes
affected by it. Calcium influx induces the cleavage of immature calpains
(pro-calpains) to form functional calpains. Calpains activate several pro-
teins involved in plasticity, learning, and memory [protein kinase C
(PKC), calcium–calmodulin kinases II isoform (CaMKII), protein phos-
phatase 3α/calcineurin (PP3α)] by limited proteolysis. The activation of
these enzymes and their respective biochemical pathwaysmodulates gene
transcription. DNA indicated by red line. CREB = cyclic adenosine
monophosphate (cAMP)-responsive element-binding protein; CRE =
cAMP response element; CBP = CREB binding protein; p = phospho
group
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confirms the efficiency of the epoxide derivatives toward AD.
Other inhibitors such as AK 295 or MDL 28170 have never
been thoroughly characterized as AD therapeutics, although
MDL 28170 is known to inhibit γ-secretase, responsible for
the cleavage of APP to produce Aβ [172, 173]. Another orally
active and very promising compound is A-705253, a
benzoylalanine-derived ketoamide that is under intense scrutiny
and characterization. A-705253 proved to be active in the
prevention of both tau phosphorylation and cleavage [174,
175], and it is active in the 3xTgAD mouse model rescuing
memory defects, reducing levels of BACE enzyme and Aβ
deposits, decreasing overall neuroinflammation [174, 176].
Taken together, these data suggest that calpain inhibition might
be an efficient and reliable target for AD therapy.
HDACs and HATs
During memory formation CREB binds to CBP, an enzyme
with HAT activity, representing one of the epigenetic process-
es leading to chromatin remodeling and DNA transcription
(Fig. 5). CBP belongs to 1 of the 5 major HAT groups: CBP/
p300; Gcn5-related N-acetyltransferases (including Gcn5 and
p300/CBP-associated factor); MYST (MOZ, Ybf2, Sas2, and
Tip60); nuclear receptor-associated HATs; and transcription
factor-related HATs [177]. On the other side, HDACs function
to remove acetyl groups from histone lysines, repressing gene
transcription. The HDAC family comprises 18 members,
grouped into 4 classes: HDAC I (HDACs 1–3 and HDAC8);
HDAC II, which is divided into IIA (HDAC4, HDAC5,
HDAC7, and HDAC9) and IIB (HDAC6 and HDAC10);
HDAC III (Sirt 1–7); and HDAC IV (HDAC11) [177, 178].
In the last decade the correlation between learning and mem-
ory and histone acetylation has been deeply explored [8–12].
Studies have shown that acetylation levels of histone 3 and
histone 4 are increased during spatial and associative learning
in the hippocampus and cortex [8, 179, 180]. The increase of
histone acetylation levels leads to transcription of memory-
promoting genes, such as cFos, BDNF-IV, EGR1, and Nr4a1
and Nr4a2 [181–184] (Fig. 5). Regulation of gene transcrip-
tion via modification of chromatin structure has been of par-
ticular interest for the treatment of various diseases. Recently,
the alteration of HDAC and HAT activity by using small
molecules, that is HDAC inhibitors and HAT activators, has
been considered as a possible therapeutic avenue for the
treatment of AD [185, 186].
Alteration of histone acetylation levels are related to the
processes of memory consolidation [8–13]. A number of studies
have focused on the role of HDAC inhibitors (HDACi) in
enhancing LTP and long-term memory (LTM) in rodents and
mutant mouse models. Synaptic plasticity was increased in hip-
pocampus slices, from APP/PS1 mice, perfused with trichostatin
A (TSA), a well-known class I/II HDACi [186]. Also, in a
contextual fear conditioning assessment, TSA was shown to
rescue spatial memory deficits in APP/PS1 mice [186]. Both
TSA and sodium butyrate (class I/II HDACi) were able to
ameliorate LTP in hippocampus slices from Sprague–Dawley
rats [8]. In addition, sodium butyrate enhanced freezing in
Sprague–Dawley rats and in CK-p25 mutant mice [8, 179],
and improved the LTM of cbp mutant mice in a novel object
recognition task [187]. Another study showed that in a visual-
paired comparison task CBPmutant mice (in whichHATactivity
is eliminated) displayed impaired LTM, which was rescued after
treatment with TSA [11]. Mutant mice that express a truncated
form of CBP (cbp+/–) showed impaired LTM in novel object
recognition task and reduced synaptic plasticity than wild-type
mice. Treatment with suberoylanilide hydroxamic acid (HDAC
I/HDAC II inhibitor) rescuedmemory deficits and increased LTP
in slices of hippocampus [9]. Consistent with previous results,
treatment with the HDACi sodium 4-phenylbutyrate restored
synaptic plasticity and memory impairment in Tg2576 mice
[188]. To define the molecular pathways underlying histone
acetylation modifications during memory consolidation, Vecsey
et al. [184] demonstrated that the interaction between CREB and
the transcriptional coactivator CBP was required to enhance the
LTP after treatment with HDACi. They found that TSAwas not
able to enhance LTP or freezing levels in CREBαΔ and cbpKIX/
KIX mutant mice in which the formation of the CREB–CBP
complexwas disrupted.Moreover, TSA enhanced the expression
ofNr4a1 andNr4a2 after fear conditioning inwild-typemice but
not in CREBαΔmutant mice, suggesting thatNr4a1 andNr4a2
expression was CREB–CBP dependent after contextual fear
conditioning. To investigate whether the CBP homolog, the
transcriptional coactivator p300, was also involved in LTM
formation, Oliveira et al. [189] tested a transgenic mice model,
p300Δ1, in which the HAT domain of the p300 protein was
truncated. These transgenic mice showed impairment in recog-
nition and contextual fear memory, demonstrating that p300 was
required in the gene transcription induced by learning processes.
Fig. 5 A schematic representation of the histone acetyltransferases
(HAT)/histone deacetylases (HDAC) system. HATs add acetyl groups
(Ac) to histones, reducing the binding of DNA to the histones. DNA
becomes accessible for the transcription of memory-related genes. Con-
versely, HDACs remove acetyl groups from histone proteins, preventing
DNA transcription
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It also been reported that loss of p300/CBP-associated factor
leads to LTM deficits in 6- and 12-month-old mice [190]. Thus,
HATactivity seems to be necessary for establishing LTM forma-
tion and consolidation owing to its involvement in learning-
dependent chromatin remodeling. Lately, an alternative approach
to modulating the acetylation levels of histones has been repre-
sented by employing small HAT activator molecules for treating
neurodegenerative disorders [177]. A few HAT activators have
been discovered and 2 of them used for studying brain functions
in vivo [191, 192]. Wei et al. [191] evaluated the effects of a
PCAF activator, SPV106, on fear conditioning and extinction.
As a result, PCAF activity was found to facilitate the formation
of fear extinction memory without affecting fear acquisition.
Instead, Chatterjee et al. [192] reported the beneficial implica-
tions of TTK21, a p300/CBP activator, on LTMby testing spatial
learning and memory in the Morris water maze task. Overall,
molecules able tomodulate the levels of histone acetylation, such
as HDACi and HAT activators, represent a promising approach
for treating cognitive aspects of neurodegenerative disorders.
Despite the growing interest in investigating how chromatin
manipulation lies behind the processes of learning and memory,
further effort is still required in terms of drug design, specificity,
and brain targeting.
Conclusions
Over the last 15 years a large amount of work has been
performed on CREB and its possible exploitation for a therapy
against AD. When our laboratories and others started this
research, the use of drugs enhancing CREB activation was
envisioned as a strategy that could work at the downstream
level of Aβ and was therefore probably devoid of any putative
side effect due the physiological function/s of APP and its
downstream products, as well as the secretases responsible for
APP processing [19, 20, 193–197]. Nevertheless, should
drugs acting onto amyloid deposition or even drugs interfering
with NFT formation provide a safe and effective approach
against AD, one can envision a scenario in which agents
enhancing CREB activation are given in a combination ther-
apy with anti-Aβ and/or anti-tau therapies.
Given all of the success in rescuing memory through CREB
function in AD, an important question should be asked: Is there
any downside to chronically increasing CREB phosphoryla-
tion? It is also important to remember that CREB is involved in
a wide range of physiological processes in a range of tissues
[198], and that CREB is also an oncogene [199]. Moreover, one
can predict that our knowledge of the regulation of CREB will
evolve with time as new studies unravel novel aspects of the
complex mechanisms regulating its activation and elucidate its
role in learning and memory. These caveats have led some to
question whether a CREB-centric approach is a viable thera-
peutic strategy at all [198]. These are important issues.
However, it is important to realize that we are not advocating
for long-term pharmacologic elevation of CREB activity above
normal levels, but rather to rescue the impairment in CREB
phosphorylation seen in AD. Thus, although the ultimate test
will be clinical trial data, there is reason to suspect that a CREB-
centric approach will be successful.
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